Improved cardiac function after sirolimus-eluting stent placement in diabetic patients by pioglitazone: Combination therapy with statin

Journal of Cardiology

Volumn 53, Issue 3, 2009, Pages 402-409

  Ozawa, Takuya ^a   Oda, Hirotaka ^a   Oda, Masato ^a   Hosaka, Yukio ^a   Kashimura, Takeshi ^a   Ozaki, Kazuyuki ^a   Tsuchida, Keiichi ^a   Takahashi, Kazuyoshi ^a   Miida, Tsutomu ^a   Aizawa, Yoshifusa ^b  

^a NIIGATA CITY GENERAL HOSPITAL   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Angioplasty; Cardiac function; Diabetes mellitus; Drug eluting stent; Thiazolidinediones

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRATE; PIOGLITAZONE; RAPAMYCIN; SULFONYLUREA; TICLOPIDINE; TRIACYLGLYCEROL;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG ELUTING STENT; FEMALE; HEART CATHETERIZATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICULOGRAPHY; HUMAN; IN-STENT RESTENOSIS; LABORATORY TEST; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; COMBINED MODALITY THERAPY; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PPAR GAMMA; SIROLIMUS; STROKE VOLUME; THIAZOLIDINEDIONES; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 67349218739     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2009.01.011     Document Type: Article

References (25)

1. Katayama T., Nakashima H., Takagi C., Honda Y., Suzuki S., Iwasaki Y., and Yano K. Clinical outcomes and left ventricular function in diabetic patients with acute myocardial infarction treated by primary coronary angioplasty. Int Heart J 46 (2005) 607-618
2. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., Molnàr F., Falotico R., and RAVEL Study Group. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
3. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., Jaeger J.L., Kuntz R.E., and SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
4. Moussa I., Leon M.B., Baim D.S., O'Neill W.W., Popma J.J., Buchbinder M., Midwall J., Simonton C.A., Keim E., Wang P., Kuntz R.E., and Moses J.W. Impact of sirolimus-eluting stents on outcome in diabetic patients A SIRIUS (SIRolImUS-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109 (2004) 2273-2278
5. Yang T.H., Park S.W., Hong M.K., Park D.W., Park K.M., Kim Y.H., Han K.H., Lee C.W., Cheong S.S., Kim J.J., and Park S.J. Impact of diabetes mellitus on angiographic and clinical outcomes in the drug-eluting stents era. Am J Cardiol 96 (2005) 1389-1392
6. Daemen J., Wenaweser P., Tsuchida K., Abrecht L., Vaina S., Morger C., Kukreja N., Jüni P., Sianos G., Hellige G., van Domburg R.T., Hess O.M., Boersma E., Meier B., Windecker S., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
7. Togni M., Windecker S., Cocchia R., Wenaweser P., Cook S., Billinger M., Meier B., and Hess O.M. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46 (2005) 231-236
8. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefèbvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
9. Martens F.M., Visseren F.L., de Koning E.J., and Rabelink T.J. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 46 (2005) 773-778
10. Pistrosch F., Herbrig K., Oelschlaegel U., Richter S., Passauer J., Fischer S., and Gross P. PPARγ-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 183 (2005) 163-167
11. Verma S., Kuliszewski M.A., Li S.H., Szmitko P.E., Zucco L., Wang C.H., Badiwala M.V., Mickle D.A., Weisel R.D., Fedak P.W., Stewart D.J., and Kutryk M.J. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109 (2004) 2058-2067
12. Wang C.H., Ting M.K., Verma S., Kuo L.T., Yang N.I., Hsieh I.C., Wang S.Y., Hung A., and Cherng W.J. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am Heart J 152 (2006) 1051.e1-1051.8
13. Huang P.H., Sata M., Nishimatsu H., Sumi M., Hirata Y., and Nagai R. Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice. Biomed Pharmacother 62 (2008) 46-52
14. Satoh N., Ogawa Y., Usui T., Tagami T., Kono S., Uesugi H., Sugiyama H., Sugawara A., Yamada K., Shimatsu A., Kuzuya H., and Nakao K. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26 (2003) 2493-2499
15. Hung Y.J., Lin S.H., Pei D., Kuo S.W., Hsieh C.H., He C.T., Hsing Lee C., Fan S.C., and Sheu W.H. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein. Metabolism 55 (2006) 439-444
16. Cubbon R.M., Rajwani A., and Wheatcroft S.B. The impact of insulin resistance on endothelial function, progenitor cells and repair. Diab Vasc Dis Res 4 (2007) 103-111
17. Frantz S., Hu K., Widder J., Bayer B., Witzel C.C., Schmidt I., Galuppo P., Strotmann J., Ertl G., and Bauersachs J. Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol 141 (2004) 9-14
18. Shiomi T., Tsutsui H., Hayashidani S., Suematsu N., Ikeuchi M., Wen J., Ishibashi M., Kubota T., Egashira K., and Takeshita A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106 (2002) 3126-3132
19. Wayman N.S., Hattori Y., McDonald M.C., Mota-Filipe H., Cuzzocrea S., Pisano B., Chatterjee P.K., and Thiemermann C. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 16 (2002) 1027-1040
20. Wynne A.M., Mocanu M.M., and Yellon D.M. Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK. J Cardiovasc Pharmacol 46 (2005) 817-822
21. Sambanis C., Tziomalos K., Kountana E., Kakavas N., Zografou I., Balaska A., Koulas G., Karagiannis A., and Zamboulis C. Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. Acta Diabetol 45 (2008) 23-30
22. Yokoyama J., Sutoh N., Higuma T., Horiuchi D., Katoh C., Yokota T., Echizen T., Sasaki S., Hanada H., Osanai T., and Okumura K. Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance. Heart Vessels 22 (2007) 146-151
23. Ye Y., Lin Y., Atar S., Huang M.H., Perez-Polo J.R., Uretsky B.F., and Birnbaum Y. Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am J Physiol Heart Circ Physiol 291 (2006) H1158-H1169
24. Yarom R., Zirkin H., Stämmler G., and Rose A.G. Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy material. J Pathol 166 (1992) 265-270
25. Dormond O., Madsen J.C., and Briscoe D.M. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem 282 (2007) 23679-23686